Document is current
Any future updates will be listed below
-
Authors
Tatarova, Zuzana https://orcid.org/0000-0002-3128-7214
Blumberg, Dylan C.
Korkola, James E.
Heiser, Laura M. https://orcid.org/0000-0003-3330-0950
Muschler, John L.
Schedin, Pepper J. https://orcid.org/0000-0003-4244-987X
Ahn, Sebastian W.
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Coussens, Lisa M. https://orcid.org/0000-0003-2389-1865
Jonas, Oliver
Gray, Joe W. https://orcid.org/0000-0001-9225-6756
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U54 CA209988, U54 CA209988, U54 CA 209988, R01 CA223150, R01 CA223150, U54 CA209988)
Susan G. Komen (SAC190012)
- License Information
-
More Information
Article History
Received: 5 November 2021
Accepted: 31 May 2022
First Online: 4 July 2022
Competing interests
: J.E.K. is a cofounder and stockholder of Convergent Genomics. G.B.M. has licensed technologies to Myriad Genetics and Nanostring; is on the Scientific Advisory Board or is a consultant to AstraZeneca, Chrysallis Biotechnology, BlueDot, Ellipses Pharma, ImmunoMET, Infinity, Medacorp, Ionis, Lilly, PDX Pharmaceuticals, Nanostring, Signalchem Lifesciences, Tarveda, Turbine, Amphista, Astex and Zentalis Pharmaceuticals; and has stock/options/financial interests in Catena Pharmaceuticals, ImmunoMet, SignalChem, Turbine, Bluedot, Nuvectis and Tarveda. Sponsored Research from AstraZeneca, Nanostring Center of Excellence and Ionis (provision of tool compounds). L.M.C. reports consulting activities for Cell Signaling Technologies, Shasqi and AbbVie; received reagent and/or research support from Cell Signaling Technologies, Syndax Pharmaceuticals, ZellBio, I and Acerta Pharma; and is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Verseau Therapeutics, CytomX Therapeutics, Kineta, Hibercell, Cell Signaling Technologies, Alkermes, PDX Pharmaceuticals, Genenta Sciences and Pio Therapeutics. O.J. is a consultant to Kibur Medical, which is developing aspects of the IMD approach described in this paper for clinical deployment. O.J.ʼs interests were reviewed and are managed by BWH and Mass General Brigham in accordance with their conflict of interest policies. J.W.G. has licensed technologies to Abbott Diagnostics, PDX Pharmaceuticals and Zorro Bio; has ownership positions in Convergent Genomics, Health Technology Innovations, Zorro Bio and PDX Pharmaceuticals; serves as a paid consultant to New Leaf Ventures; has received research support from Thermo Fisher Scientific, Zeiss, Miltenyi Biotec, Quantitative Imaging, Health Technology Innovations and Micron Technologies; and owns stock in Abbott Diagnostics, AbbVie, Alphabet, Amazon, AMD, Amgen, Apple, Berkshire Hathaway, Cisco Systems, Clorox, Colgate Palmolive, Crown Castle International, Humana, Keysight, Linde, Proctor and Gamble, Qualcomm, Unilever, Gilead, Intel, Johnson & Johnson, Microsoft, Nvidia, Taiwan Semiconductor and Zimmer Biomet. The other authors declare no competing interests.
